Critically, the combination of polyclonal CD8+ T cell responses and polyvalent antigen recognition by NKG2D directly targets the fundamental challenges of tumor heterogeneity and recurrence in HCC therapy, offering a solution to overcome therapeutic resistance. This evidence concerns the gene CD8A and hepatocellular carcinoma.